These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38376107)

  • 41. First report on the safety and efficacy of an extended half-life glycoPEGylated recombinant FVIII for major surgery in severe haemophilia A.
    Hampton K; Chowdary P; Dunkley S; Ehrenforth S; Jacobsen L; Neff A; Santagostino E; Sathar J; Takedani H; Takemoto CM; Négrier C
    Haemophilia; 2017 Sep; 23(5):689-696. PubMed ID: 28470862
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Long-term patterns of safety and efficacy of bleeding prophylaxis with turoctocog alfa (NovoEight(®) ) in previously treated patients with severe haemophilia A: interim results of the guardian(™) 2 extension trial.
    Ozelo M; Misgav M; Abdul Karim F; Lentz SR; Martin-Salces M; Matytsina I; Saugstrup T; Santagostino E
    Haemophilia; 2015 Sep; 21(5):e436-9. PubMed ID: 26058730
    [No Abstract]   [Full Text] [Related]  

  • 43. Bleeding and safety outcomes in persons with haemophilia A without inhibitors: Results from a prospective non-interventional study in a real-world setting.
    Kruse-Jarres R; Oldenburg J; Santagostino E; Shima M; Kempton CL; Kessler CM; Lehle M; Chebon S; Selak Bienz N; Asikanius E; Mahlangu J
    Haemophilia; 2019 Mar; 25(2):213-220. PubMed ID: 30724422
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Octocog alfa, antihaemophilic factor (recombinant), plasma/albumin free method (Advate®): a review of its use in the management of patients with haemophilia A.
    Dhillon S
    Drugs; 2012 May; 72(7):987-1007. PubMed ID: 22564135
    [TBL] [Abstract][Full Text] [Related]  

  • 45. BAY 81-8973 safety and efficacy for prophylaxis and treatment of bleeds in previously treated children with severe haemophilia A: results of the LEOPOLD Kids Trial.
    Ljung R; Kenet G; Mancuso ME; Kaleva V; Rusen L; Tseneklidou-Stoeter D; Michaels LA; Shah A; Hong W; Maas Enriquez M;
    Haemophilia; 2016 May; 22(3):354-60. PubMed ID: 26663410
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Interim data on long-term efficacy, safety and tolerability of a plasma-derived factor VIII concentrate in 109 patients with severe haemophilia A.
    Nemes L; Pollmann H; Becker T
    Haemophilia; 2012 Jul; 18(4):496-502. PubMed ID: 22250808
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Turoctocog alfa for the treatment of hemophilia a.
    Vakil NH; Fujinami N; Martin-Stone S
    Pharmacotherapy; 2014 Oct; 34(10):1091-101. PubMed ID: 25052207
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacokinetics and pharmacodynamics of turoctocog alfa and N8-GP in haemophilia A dogs.
    Agersø H; Stennicke HR; Pelzer H; Olsen EN; Merricks EP; Defriess NA; Nichols TC; Ezban M
    Haemophilia; 2012 Nov; 18(6):941-7. PubMed ID: 22812621
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacokinetics, immunogenicity, safety, and preliminary efficacy of subcutaneous turoctocog alfa pegol in previously treated patients with severe hemophilia A (alleviate 1).
    Klamroth R; Feistritzer C; Friedrich U; Lentz SR; Reichwald K; Zak M; Chowdary P
    J Thromb Haemost; 2020 Feb; 18(2):341-351. PubMed ID: 31618804
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inhibitor development, safety, and efficacy of Advate
    Taki M; Fukutake K; Matsushita T; Nogami K; Shima M; Yoshioka A; Takamatsu J; Arai M; Takagi H; Uchikawa H; Engl W; Shirahata A
    Int J Hematol; 2019 Jan; 109(1):70-78. PubMed ID: 30043332
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Development of a tail vein transection bleeding model in fully anaesthetized haemophilia A mice - characterization of two novel FVIII molecules.
    Johansen PB; Tranholm M; Haaning J; Knudsen T
    Haemophilia; 2016 Jul; 22(4):625-31. PubMed ID: 26936336
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The safety and efficacy of N8-GP (turoctocog alfa pegol) in previously untreated pediatric patients with hemophilia A.
    Male C; Königs C; Dey S; Matsushita T; Millner AH; Zak M; Young G; Kenet G
    Blood Adv; 2023 Feb; 7(4):620-629. PubMed ID: 35858373
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Simoctocog Alfa (Nuwiq) in Previously Untreated Patients with Severe Haemophilia A: Final Results of the NuProtect Study.
    Liesner RJ; Abraham A; Altisent C; Belletrutti MJ; Carcao M; Carvalho M; Chambost H; Chan AKC; Dubey L; Ducore J; Gattens M; Gresele P; Gruel Y; Guillet B; Jimenez-Yuste V; Kitanovski L; Klukowska A; Lohade S; Mancuso ME; Oldenburg J; Pavlova A; Pollio B; Sigaud M; Vdovin V; Vilchevska K; Wu JKM; Jansen M; Belyanskaya L; Walter O; Knaub S; Neufeld EJ
    Thromb Haemost; 2021 Nov; 121(11):1400-1408. PubMed ID: 33581698
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Continuous infusions of B domain-truncated recombinant factor VIII, turoctocog alfa, for orthopedic surgery in severe hemophilia A: first case report.
    Takeyama M; Nogami K; Kobayashi R; Ogiwara K; Taniguchi A; Nakanishi Y; Inagaki Y; Tanaka Y; Shima M
    Int J Hematol; 2018 Aug; 108(2):199-202. PubMed ID: 29383626
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cases of less-than-expected FVIII activity in previously treated patients during post-marketing surveillance of N8-GP.
    Oldenburg J; Benson G; Chowdary P; Halimeh S; Matsushita T; Nørland A; Wahid MN; Nemes L
    Haemophilia; 2023 Nov; 29(6):1475-1482. PubMed ID: 37729439
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A postmarketing surveillance study of the safety and efficacy of ReFacto (St Louis-derived active substance) in patients with haemophilia A.
    Smith MP; Giangrande P; Pollman H; Littlewood R; Kollmer C; Feingold J;
    Haemophilia; 2005 Sep; 11(5):444-51. PubMed ID: 16128886
    [TBL] [Abstract][Full Text] [Related]  

  • 57. PROTECT VIII kids extension study: Long-term safety and efficacy of BAY 94-9027 (damoctocog alfa pegol) in children with severe haemophilia A.
    Mancuso ME; Biss T; Fischer K; Maas Enriquez M; Steele M; Wang M; Tseneklidou-Stoeter D; Ahuja S; Kenet G
    Haemophilia; 2021 May; 27(3):434-444. PubMed ID: 33724632
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Continued benefit demonstrated with BAY 81-8973 prophylaxis in previously treated children with severe haemophilia A: Interim analysis from the LEOPOLD Kids extension study.
    Kenet G; Ljung R; Rusen L; Kerlin BA; Blanchette V; Saulytė Trakymienė S; Uscatescu V; Beckmann H; Tseneklidou-Stoeter D; Church N
    Thromb Res; 2020 May; 189():96-101. PubMed ID: 32197139
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 vs two recombinant factor VIII for the prophylactic treatment of severe hemophilia A.
    Pocoski J; Li N; Ayyagari R; Church N; Maas Enriquez M; Xiang Q; Kelkar S; Du EX; Wu EQ; Xie J
    J Blood Med; 2016; 7():129-37. PubMed ID: 27445511
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Damoctocog Alfa Pegol: A Review in Haemophilia A.
    Paik J; Deeks ED
    Drugs; 2019 Jul; 79(10):1147-1156. PubMed ID: 31218660
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.